TrialDrugs in R&D2018

Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial.

John M Slopis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.